Program
ribupatide
Also written as “HRS9531”, “HRS9531 injection” and “HRS9531 Tablet”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Kidney Failure, Chronic · Atherosclerosis · Fatty Liver, led by 2 companies.
Drug pageRibupatide: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 3214 open or running | phase 3since Apr 30, 2024 | Nov 29, 2021 | Dec 2026phase 3 · NCT06994650 |
| Kaileraits history only | 65 open or running | phase 3since Dec 9, 2025 | Jun 23, 2025 | May 2027phase 2 · NCT07458269 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
Ribupatide
, phase 4, as of Jul 31, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseKailera licensed it from Hengrui, for everywhere outside Greater China.Agreed May 2024 · Source: Kailera Therapeutics (release), Oct 1, 2024
History and studies of Jiangsu HengRui Medicine only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 18 earlier studies, Nov 29, 2021 to Dec 5, 2024.
- May 2024Kailera licensed it from HengruiLicenseEverywhere outside Greater China · agreed · Kailera Therapeutics (release)
- Jan 20, 2025Phase 1 study in OverweightNCT06792955 · 120 enrolled · China
- Feb 18, 2025Phase 2 study in Chronic Management of Body WeightNCT06841445 · 166 enrolled · China
- Feb 25, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT06855147 · 7 enrolled · China
- Apr 24, 2025Phase 3 study in Sleep Apnea, ObstructiveNCT06974851 · 140 planned · China
- May 20, 2025Phase 3 study in Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP TherapyNCT06994650 · 144 enrolled · China
- Jun 22, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07060456 · 300 planned · China
- Jul 10, 2025Named ribupatideINNProposed as its International Nonproprietary Name in WHO's List 133 · before, HRS9531
- Aug 27, 2025Phase 1 study in OverweightNCT07150962 · 168 planned · China
- Dec 3, 2025Phase 3 study in ObesityNCT07285902 · 572 enrolled · China
- Apr 13, 2026Phase 1 study in Diabetes MellitusNCT07540754 · 24 planned · China
- Apr 17, 2026Phase 3 study in AtherosclerosisNCT07551492 · 9,262 planned · China
- May 11, 2026Phase 2 study in T2DMNCT07599410 · 240 planned · China
- Jun 16, 2026Phase 2 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07660848 · 160 planned · China
- Jun 22, 2026Phase 3 study in Chronic Management of Body WeightNCT07670884 · 675 planned · China
- Jul 8, 2026Phase 3 study in Osteoarthritis, KneeNCT07709910 · 382 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP TherapyNCT06994650
- Dec 2026Primary completion: phase 3 study in Sleep Apnea, ObstructiveNCT06974851
- Jan 2027Primary completion: phase 1 study in Diabetes MellitusNCT07540754
- Feb 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07060456
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 32 Jiangsu HengRui Medicine leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07709910Osteoarthritis, Knee · China | 3 | Not yet recruiting | Nov 2028 | 382 |
| NCT07670884Chronic Management of Body Weight · China | 3 | Recruiting | Oct 31, 2027 | 675 |
| NCT07660848Metabolic Dysfunction-Associated Steatohepatitis (MASH) · China | 2 | Recruiting | Mar 2028 | 160 |
| NCT07599410T2DM · China | 2 | Recruiting | May 2027 | 240 |
| NCT07551492Atherosclerosis · China | 3 | Recruiting | May 24, 2031 | 9,262 |
| NCT07540754Diabetes Mellitus · China | 1 | Recruiting | Jan 2027 | 24 |
| NCT07285902Obesity · China | 3 | Active, not recruiting | Mar 2027 | 572 |
| NCT07150962Overweight · China | 1 | Recruiting | Feb 2026 | 168 |
| NCT07060456Diabetes Mellitus, Type 2 · China | 3 | Recruiting | Feb 2027 | 300 |
| NCT06994650Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy · China | 3 | Active, not recruiting | Dec 2026 | 144 |
| NCT06974851Sleep Apnea, Obstructive · China | 3 | Recruiting | Dec 2026 | 140 |
| NCT06855147Diabetes Mellitus, Type 2 · China | 1 | Completed | Jun 17, 2025 | 7 |
| NCT06841445Chronic Management of Body Weight · China | 2 | Completed | Jan 8, 2026 | 166 |
| NCT06792955Overweight · China | 1 | Completed | Jun 6, 2025 | 120 |
| NCT06762600Overweight · China | 1 | Completed | Mar 12, 2026 | 102 |
| NCT06723691Diabetes Mellitus, Type 2 · China | 1 | Completed | Jun 9, 2025 | 57 |
| NCT06654960Diabetes Mellitus, Type 2 · China | 1 | Completed | Dec 26, 2024 | 20 |
| NCT06650007Diabetes Mellitus, Type 2 · China | 3 | Completed | Jan 21, 2026 | 218 |
| NCT06649344Diabetes Mellitus, Type 2 · China | 3 | Completed | Jul 18, 2026 | 884 |
| NCT06595797Obese Subjects With Polycystic Ovary Syndrome (PCOS) | 2 | UNKNOWN | Dec 2025 | 144 |
| NCT06565871Weight Management | 2 | Not yet recruiting | Dec 2025 | 108 |
| NCT06506175Diabetes Mellitus, Type 2 · China | 1 | Not yet recruiting | Sep 2026 | 100 |
| NCT06435676Overweight · China | 1 | Completed | Oct 8, 2024 | 72 |
| NCT06396429Overweight · China | 3 | Completed | Jul 7, 2025 | 567 |
| NCT06391710Heart Failure With Preserved Ejection Fraction · China | 2 | Active, not recruiting | Jan 2026 | 203 |
| NCT06246175Diabetes Mellitus, Type 2 · China | 1 | Completed | Sep 2, 2025 | 32 |
| NCT06054698Overweight · China | 2 | Completed | Sep 9, 2024 | 61 |
| NCT05966272Diabetes Mellitus, Type 2 · China | 2 | Completed | Sep 24, 2024 | 199 |
| NCT05881837Overweight · China | 2 | Completed | Oct 13, 2024 | 249 |
| NCT05893576Diabetes Mellitus, Type 2 · China | 1 | Completed | Sep 4, 2023 | 50 |
| NCT05516966Diabetes Mellitus, Type 2 · China | 1 | Completed | May 24, 2023 | 64 |
| NCT05152277Diabetes Mellitus, Type 2 · China | 1 | Completed | Aug 24, 2022 | 90 |
How it is read
Names in the registry
- “HRS9531”, 16 entries
- “HRS9531 injection”, 14 entries
- “HRS9531 Tablet”, 9 entries
- “HRS9531 Injection”, 6 entries
- “Ribupatide”, 5 entries
Codes read as this program: HRS9531.
Conditions, from the studies’ own filings
- Obesity, 13 studies
- Diabetes Mellitus, Type 2, 12 studies
- Kidney Failure, Chronic, 1 study
- Atherosclerosis, 1 study
- Fatty Liver, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.